reviewAmerican Journal of PsychiatryJan 15, 2025GREEN OA

Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?

Johns Hopkins University · Johns Hopkins Medicine · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Ketamine is a racemic compound and medication comprised of (S)-ketamine and (R)-ketamine enantiomers and its metabolites. It has been used for decades as a dissociative anesthetic, analgesic, and recreational drug. More recently, ketamine, its enantiomers, and its metabolites have been used or are being investigated for the treatment of refractory depression, as well as for comorbid disorders such as anxiety, obsessive-compulsive, and opioid use disorders. Despite its complex pharmacology, ketamine is referred to as an N-methyl-d-aspartate (NMDA) receptor antagonist. In this review, the authors argue that ketamine’s pharmacology should be redefined to include opioid receptors and the endogenous opioid system.…

No related works found for this paper.